Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.98 USD | +5.88% | -1.01% | -8.17% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.17% | 516M | |
-1.93% | 103B | |
+0.23% | 95.71B | |
+1.69% | 22.02B | |
-17.03% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.82% | 15.52B | |
+3.59% | 13.86B | |
+34.80% | 12.04B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio to Halt Imsidolimab Development for Acne After Trial; Shares Plunge 13% After Hours